Coherus Rep Discusses Interchangeable Ophthalmology Biosimilar, Previews Onpro Competitor
September 28th 2022
By Skylar JeremiasVideo
Part 5 available now!
Paul Reider, MBA, chief commercial officer at Coherus Biosciences, chronicles why Coherus got an interchangeable designation for its ophthalmology biosimilar, how it plans to set its adalimumab biosimilar apart from the rest, and when the pegfilgrastim market could see a competitor for Neulasta Onpro.